OBJECTIVE: To report a case of acute elevation of hepatic enzyme levels as a probable adverse reaction associated with pregabalin. CASE SUMMARY: A 59-year-old man with a history of mantle cell lymphoma developed neuropathic pain and was treated with pregabalin 25 mg daily. Fourteen days after beginning pregabalin therapy, he developed left ankle edema and elevation of liver enzyme levels. Peak values were aspartate transaminase 907 U/L, alanine transaminase 1582 U/L, and γ-glutamyltransferase 510 U/L. Pregabalin was discontinued and hepatic enzyme levels returned gradually (over 4 months) to baseline levels. DISCUSSION: Many medications are commonly associated with liver injury; few cases of pregabalin-associated hepatotoxicity have been documented. A MEDLINE search (1966-November 2010) revealed 2 reports of acute liver injury with the initiation of pregabalin. In our patient, with hemosiderosis after hematopoietic cell transplantation, pregabalin worsened the underlying liver injury. The low pregabalin dosage and the short time to elevation of liver enzyme levels suggest an idiosyncratic reaction. According to the Naranjo probability scale and the Council for International Organizations of Medical Sciences probability scale, this reaction was probably due to pregabalin. CONCLUSIONS: Prescribers should be alert to the possibility of idiosyncratic hepatotoxicity associated with pregabalin use.
OBJECTIVE: To report a case of acute elevation of hepatic enzyme levels as a probable adverse reaction associated with pregabalin. CASE SUMMARY: A 59-year-old man with a history of mantle cell lymphoma developed neuropathic pain and was treated with pregabalin 25 mg daily. Fourteen days after beginning pregabalin therapy, he developed left ankle edema and elevation of liver enzyme levels. Peak values were aspartate transaminase 907 U/L, alanine transaminase 1582 U/L, and γ-glutamyltransferase 510 U/L. Pregabalin was discontinued and hepatic enzyme levels returned gradually (over 4 months) to baseline levels. DISCUSSION: Many medications are commonly associated with liver injury; few cases of pregabalin-associated hepatotoxicity have been documented. A MEDLINE search (1966-November 2010) revealed 2 reports of acute liver injury with the initiation of pregabalin. In our patient, with hemosiderosis after hematopoietic cell transplantation, pregabalin worsened the underlying liver injury. The low pregabalin dosage and the short time to elevation of liver enzyme levels suggest an idiosyncratic reaction. According to the Naranjo probability scale and the Council for International Organizations of Medical Sciences probability scale, this reaction was probably due to pregabalin. CONCLUSIONS: Prescribers should be alert to the possibility of idiosyncratic hepatotoxicity associated with pregabalin use.
Authors: Vatsalya Vatsalya; Akash Pandey; Melanie L Schwandt; Matthew C Cave; Shirish S Barve; Vijay A Ramchandani; Craig J McClain Journal: Clin Drug Investig Date: 2016-11 Impact factor: 2.859
Authors: Anna Rapacz; Anna M Waszkielewicz; Katarzyna Pańczyk; Karolina Pytka; Paulina Koczurkiewicz; Kamil Piska; Elżbieta Pękala; Bogusława Budziszewska; Beata Starek-Świechowicz; Henryk Marona Journal: Medchemcomm Date: 2016-11-11 Impact factor: 3.597